The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?
We investigated the off-patent biological market in Belgium from a policy maker’s perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator’s reach and to a concertation model with assessment and apprais...
Main Author: | Philippe Van Wilder |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/4/352 |
Similar Items
-
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
by: Yannick Vandenplas, et al.
Published: (2022-09-01) -
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
by: Yannick Vandenplas, et al.
Published: (2023-07-01) -
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022-12-01) -
Dynamics of price competition in Italian pharmaceutical off-patent market
by: Serena Perna, et al.
Published: (2022-11-01) -
Documents illustrating the history of Belgium /
Published: (1978)